Foghorn (FHTX) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $16.1M
- Revenue growth (year over year)
- +112.68%
- Gross margin
- 100.00%
- Net income (quarter)
- −$7.2M
- Net margin
- −175.78%
- Book value per share
- −$1.38
- Debt to assets
- 139.84%
Company profile
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Frequently asked questions
Is Foghorn (FHTX) profitable?
No. Foghorn reported a net loss of $64.6M over the trailing twelve months.
How much revenue does Foghorn (FHTX) make?
Foghorn generated $36.7M in revenue over the trailing twelve months, up 112.68% year over year.
How do I buy stock in Foghorn (FHTX)?
FHTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.